American Journal of Biomedicine and Pharmacy
https://biojournals.us/index.php/AJBP
ISSN: 2997-7177

Caffeine Metabolism and its Effects on Brain Biochemistry

Valijonova Ma'mura*[1]
1. Department of Biochemistry, School of Medicine
*Correspondence: smilinggirl2788@gmail.com

Citation: Ma'mura, V. Caffeine Metabolism and its Effects on Brain Biochemistry. American Journal of Biomedicine and Pharmacy 2026, 3(5), 42-48.

Received: 28th Mar 2026
Revised: 15th Apr 2026
Accepted: 25th Apr 2026
Published: 09th May 2026

Abstract: Caffeine (1,3,7-trimethylxanthine) holds the distinction of being the most broadly consumed neuroactive substance in recorded human history, with habitual intake documented across diverse geographic, cultural, and socioeconomic populations. Despite its familiarity, the molecular pharmacology underlying its central nervous system effects involves a constellation of biochemical events that extend considerably beyond simple neuronal stimulation. This narrative review synthesizes peer-reviewed evidence published between 2021 and 2026 to address four principal questions: (i) how hepatic cytochrome P450 1A2 (CYP1A2) mediates N-demethylation of caffeine into its pharmacologically active primary metabolites—paraxanthine, theobromine, and theophylline; (ii) through what structural and kinetic mechanisms caffeine competitively antagonizes adenosine A1 and A2A receptors; (iii) how that receptor-level antagonism propagates into altered dopaminergic, glutamatergic, GABAergic, and noradrenergic neurotransmission; and (iv) what the long-term neurobiological consequences of habitual intake are, including modulation of neuroplasticity and potential protective effects against Alzheimer's and Parkinson's diseases. Collectively, the evidence positions caffeine as a dose-sensitive neuromodulator whose biochemical footprint in the brain is substantially more complex than its widespread, culturally normalized status might suggest.

Keywords: Caffeine, Adenosine Receptor Antagonism, CYP1A2, Paraxanthine, Brain Biochemistry, Dopamine, Neuroplasticity, Neuroprotection

Introduction

Caffeine is a purine alkaloid of the methylxanthine class, characterized chemically by a bicyclic xanthine scaffold bearing methyl substituents at nitrogen positions 1, 3, and 7. Global production and consumption data indicate that upward of two billion caffeinated beverage servings are prepared worldwide each day, positioning caffeine far ahead of any other neuroactive compound in terms of voluntary human intake [1]. Its sources span coffee, tea, cocoa, carbonated soft drinks, energy formulations, and a range of analgesic and cold-remedy pharmaceuticals, ensuring near-universal exposure across age groups in contemporary society.

From a mechanistic standpoint, caffeine's most consequential action is its competitive interference with adenosine receptors, a class of inhibitory G-protein-coupled receptors whose endogenous ligand accumulates progressively during sustained wakefulness and metabolic activity. By occupying these receptors without activating them, caffeine counteracts adenosine's sleep-promoting and neuronal-dampening effects, thereby sustaining alertness and cognitive performance [2]. Yet this single mechanism generates ripple effects across multiple neurotransmitter systems—dopaminergic, glutamatergic, GABAergic, and noradrenergic—each contributing to caffeine's net psychophysiological profile.

Equally important is the pharmacokinetic dimension: caffeine undergoes extensive hepatic biotransformation into three structurally distinct metabolites, each possessing independent receptor affinities and physiological activities [3]. Interindividual differences in the enzyme responsible for this conversion, CYP1A2, introduce substantial variability in caffeine's effective duration of action and its associated health implications. These genetic considerations have elevated caffeine research into the domain of personalized nutrition and pharmacogenomics.

Recent years have brought a new layer of scientific interest through epidemiological and mechanistic evidence suggesting that regular caffeine consumption may confer neuroprotective benefits—specifically, a reduced population-level incidence of Alzheimer's disease (AD) and Parkinson's disease (PD) [4, 5]. The biochemical plausibility of these associations rests on caffeine's capacity to modulate amyloid precursor processing, tau phosphorylation kinetics, and neuroinflammatory cascades, all of which are central to both pathologies. The present review provides a structured synthesis of the most current evidence across these domains, with the goal of offering a mechanistically coherent picture of caffeine's role as a neuroactive molecule.

Materials and Methods

This paper is structured as a narrative review of primary and secondary scientific literature. Systematic database searches were conducted across PubMed/MEDLINE, Web of Science, and Google Scholar using the following Boolean search strings: "caffeine AND metabolism"; "caffeine AND adenosine receptor"; "CYP1A2 AND caffeine pharmacokinetics"; "paraxanthine AND brain"; "caffeine AND neuroprotection"; "caffeine AND Alzheimer's disease"; "caffeine AND Parkinson's disease"; and "caffeine AND cognitive performance." The temporal filter was restricted to publications from January 2021 through April 2026 to ensure clinical and scientific currency.

Inclusion was limited to original research articles, systematic reviews, and quantitative meta-analyses published in peer-reviewed English-language journals. Conference proceedings, opinion pieces, letters, and sources lacking peer review were excluded. An initial screening of 47 candidate articles was performed based on title and abstract relevance; 16 sources met all eligibility criteria and are incorporated in the final synthesis. Study quality was informally evaluated with reference to sample size adequacy, methodological transparency, and consistency with the mechanistic framework under review.

Results

A. Pharmacokinetics and Hepatic Metabolism

Oral caffeine is absorbed rapidly from the upper gastrointestinal tract, reaching maximal plasma concentrations within 30 to 60 minutes of ingestion. Its notably low molecular weight (194.19 g/mol) combined with moderate lipophilicity allows unrestricted diffusion across the blood-brain barrier, ensuring that central nervous system concentrations track closely with peripheral plasma levels [3]. The volume of distribution is approximately 0.6 L/kg, indicating fairly uniform tissue penetration, with the half-life in healthy non-pregnant adults averaging 3 to 6 hours under typical conditions.

Biotransformation occurs almost exclusively in the liver, where the cytochrome P450 isoenzyme CYP1A2 catalyzes sequential N-demethylation reactions. Three primary metabolites arise from this process: paraxanthine (1,7-dimethylxanthine), which constitutes roughly 84% of the hepatic metabolic output; theobromine (3,7- dimethylxanthine), at approximately 12%; and theophylline (1,3-dimethylxanthine), at roughly 4% [3]. Each metabolite retains affinity for adenosine receptors, though with differing selectivity profiles. Paraxanthine is the most pharmacologically potent in terms of central adenosine antagonism, while theophylline exhibits greater bronchodilatory activity and a narrower therapeutic window. Subsequent metabolism of these primary products involves xanthine oxidase-mediated oxidation and N-acetyltransferase 2 (NAT2)-mediated acetylation, yielding methylated uric acid derivatives that undergo renal elimination.

Genetic polymorphism at the CYP1A2 locus profoundly shapes caffeine clearance rates. The single nucleotide polymorphism rs762551 (C>A) generates a functional division between "slow" metabolizers (CYP1A2*1F, CC genotype) and "fast" metabolizers (CYP1A2*1A, AA or CA genotype). In slow metabolizers, caffeine half-life may extend to 8–10 hours, producing sustained plasma levels that have been associated with elevated cardiovascular risk at equivalent doses of consumption [6]. This pharmacogenomic variability

has important implications for both individualized dietary guidance and the interpretation of population-level epidemiological findings.

B. Adenosine Receptor Antagonism: Structural and Kinetic Basis

The primary mechanism through which caffeine exerts its neuromodulatory effects is competitive, reversible antagonism at adenosine receptors—specifically the A1 and A2A subtypes. Under physiological conditions, extracellular adenosine concentrations rise proportionally with the duration and intensity of neuronal activity, reflecting ongoing ATP hydrolysis. As adenosine accumulates and increasingly occupies its cognate receptors, neuronal excitability decreases, neurotransmitter release is curtailed, cerebral vasodilation occurs, and homeostatic sleep pressure accumulates [2]. Caffeine, whose purine ring system confers structural resemblance to adenosine, binds within the orthosteric site of both receptor subtypes with sufficient affinity to competitively displace the endogenous ligand without initiating signal transduction.

Structural pharmacology investigations utilizing cryo-electron microscopy have clarified the binding mode with considerable precision. Caffeine engages the receptor pocket primarily through hydrophobic pi-stacking interactions with aromatic residues (Phe168, Leu253 in A2A) and forms a network of van der Waals contacts.

Critically, caffeine lacks the ribose moiety present in adenosine, which is required for receptor activation; this structural absence accounts for its antagonistic rather than agonistic behavior [7]. Functional Ki values for caffeine are approximately 12 μM at the A1 receptor and 2.4 μM at the A2A receptor, both well within the range achievable at typical dietary intake levels of 3–5 cups of coffee daily.

The A1 receptor is broadly distributed across cortical laminae, the hippocampus, and the cerebellum. Its occupation by adenosine normally suppresses glutamate and acetylcholine release at presynaptic terminals, providing widespread inhibitory modulation of excitatory neurotransmission. The A2A receptor, by contrast, is most highly expressed in the striatum—particularly within GABAergic medium spiny neurons of the indirect basal ganglia pathway—where its heterodimerization with the dopamine D2 receptor represents a major site of dopamine-adenosine functional interaction [8].

C. **Downstream Effects on Neurotransmitter Systems**

Dopaminergic modulation. The functional antagonism between A2A and D2 receptors in striatal circuits is among the most pharmacologically significant consequences of caffeine's mechanism of action. When adenosine occupies A2A receptors that are co-expressed with D2 receptors on indirect pathway neurons, it reduces D2 receptor affinity for dopamine and promotes inhibitory G-protein coupling. Caffeine's blockade of A2A receptors disinhibits D2 signaling, thereby facilitating dopaminergic tone in both the mesolimbic and nigrostriatal projections [8]. Positron emission tomography studies confirm measurable dopamine release in the caudate nucleus and nucleus accumbens following caffeine administration, which partly accounts for caffeine's reinforcing properties and mood-enhancing effects. This striatal A2A/D2 interplay is also mechanistically central to the observed epidemiological inverse association between habitual coffee intake and Parkinson's disease risk [5].

Glutamatergic facilitation. Blockade of presynaptic A1 receptors removes tonic inhibition from glutamate release at excitatory cortical and hippocampal synapses. The resulting increase in synaptic glutamate availability augments activation of NMDA and AMPA receptors, thereby facilitating the induction of long-term potentiation (LTP)—the primary cellular substrate of learning and memory consolidation. Park et al. [9] demonstrated that hippocampal LTP magnitude was significantly augmented by caffeine concentrations of 10– 50 μM in wild-type rodents, whereas this effect was entirely absent in A1 receptor knockout animals, confirming adenosine receptor-dependency as the causal pathway rather than a non-specific membrane effect.

GABAergic interactions. Caffeine's net impact on inhibitory neurotransmission is circuit-dependent and dose- sensitive. In cortical and hippocampal regions, A1 blockade reduces GABAergic inhibitory postsynaptic potential amplitude indirectly by allowing greater glutamatergic drive onto inhibitory interneurons, a paradoxical effect. Within the basal ganglia, A2A antagonism at indirect pathway GABAergic neurons increases their inhibitory output, contributing to the net disinhibition of motor thalamus activity. At supratherapeutic plasma concentrations rarely reached through dietary intake, caffeine has additionally been reported to interact with benzodiazepine allosteric sites on GABA-A receptors as a weak non-competitive antagonist, which may contribute to the anxiogenic effects observed at high doses [10].

Noradrenergic and other monoaminergic effects. Cortical A1 receptor antagonism promotes increased norepinephrine release in prefrontal and limbic regions, contributing to the heightened arousal, attentional engagement, and mild sympathomimetic cardiovascular effects associated with caffeine intake. While caffeine does not bind serotonin receptors directly at pharmacologically relevant concentrations, adenosine modulates serotoninergic firing rates in the dorsal raphe nucleus, and caffeine's perturbation of this regulatory system may secondarily alter serotonin dynamics in ways that partly explain mood-related effects and the anxiogenic response at high doses [1].

D. Cerebral Hemodynamics and Neural Metabolism

A hemodynamic dimension of caffeine's central pharmacology that is frequently underappreciated involves its capacity to reduce resting cerebral blood flow (CBF). Adenosine normally acts as a potent cerebral vasodilator by activating A2A receptors on smooth muscle cells of cerebral resistance arteries. Caffeine's competitive antagonism at these vascular A2A receptors produces measurable vasoconstriction, reducing resting CBF by an estimated 20–30% relative to caffeine-free baseline—an effect consistently documented by quantitative arterial spin labeling functional MRI [11]. This reduction is global rather than regionally selective and is sustained for the duration of caffeine's plasma half-life.

From a research methodology perspective, this hemodynamic effect has prompted standardized caffeine abstinence protocols prior to resting-state fMRI acquisition to prevent confounding of BOLD signal interpretation. Despite the apparent paradox of reduced perfusion coinciding with subjective cognitive improvement, current evidence suggests that caffeine may enhance the spatial precision of neurovascular coupling—the correspondence between local neural activity and regional perfusion—thereby improving signal- to-noise characteristics of neural representations even as absolute flow decreases [11]. At the metabolic level, caffeine has been found to upregulate hypoxia-inducible factor 1-alpha (HIF-1α) expression in astrocytes under energetic stress, which may contribute to cellular adaptive responses that overlap mechanistically with neuroprotection [12].

E. Dose-Dependent Cognitive and Behavioral Outcomes

The behavioral pharmacology of caffeine follows a well-characterized inverted-U dose-response relationship in which low-to-moderate doses produce meaningful cognitive enhancement while higher doses yield diminishing returns or frank performance decrements. Meta-analytic synthesis of randomized controlled trials indicates that acute caffeine doses in the range of 40–200 mg consistently improve sustained attention, visuospatial processing speed, working memory accuracy, and simple reaction time, with effects most pronounced in individuals experiencing sleep deprivation or circadian trough states [13]. These findings are highly replicable across participant populations, experimental paradigms, and caffeine delivery vehicles.

At doses exceeding approximately 400 mg, the incidence of adverse cognitive effects rises substantially. Reports of cognitive interference, attentional narrowing, task-switching impairment, motor tremor, and frank anxiety become prevalent, consistent with excessive glutamatergic excitability and adrenal activation overtaxing prefrontal regulatory capacity. The mechanistic basis for this performance reversal likely involves the same A1 receptor pathway: beyond a threshold of receptor occupancy, continued glutamatergic facilitation transitions from optimizing signal clarity to generating excitatory noise that degrades cognitive processing [13].

Regarding affective outcomes, epidemiological analyses consistently support an inverse relationship between habitual moderate caffeine intake and risk of clinically significant depressive symptomatology. A large-scale meta-analysis aggregating data from over 340,000 participants identified a dose-dependent inverse association in which each additional daily cup of coffee was linked to approximately a 7% decrement in depression risk [14]. While causality cannot be established from observational data, the mechanistic hypotheses include enhanced dopaminergic signaling in reward circuitry, anti-inflammatory activity of coffee polyphenols co- ingested with caffeine, and modulation of the hypothalamic-pituitary-adrenal (HPA) stress axis through adenosine-dependent pathways.

F. Neuroprotective Mechanisms and Long-Term Brain Health

Among the most scientifically compelling dimensions of caffeine pharmacology is its association with reduced incidence of two major neurodegenerative diseases: Alzheimer's disease (AD) and Parkinson's disease (PD).

The consistency and dose-responsiveness of these epidemiological associations, combined with mechanistic plausibility established in animal models and molecular studies, have generated substantial interest in caffeine's potential as a low-cost neuroprotective agent.

In the context of AD, adenosine A2A receptor signaling has been identified as a positive regulator of amyloid- beta (Aβ) peptide production and aggregation. Overactivation of A2A receptors augments the amyloidogenic processing of amyloid precursor protein (APP) through beta-secretase (BACE1) upregulation, while simultaneously promoting aberrant phosphorylation of tau protein via enhanced GSK-3β activity. Chronic caffeine administration in transgenic murine AD models has been shown to substantially reduce hippocampal Aβ plaque burden, attenuate tau hyperphosphorylation, improve performance on spatial memory tasks, and decrease expression of neuroinflammatory biomarkers including interleukin-6 and tumor necrosis factor-alpha [4]. Human epidemiological data from three independent cohort studies indicate a 30–40% lower risk of AD diagnosis among individuals reporting moderate-to-high habitual coffee consumption relative to non- consumers, though causal inference remains constrained by confounding and reverse causality considerations.

The neuroprotective case for PD is even more robust from an epidemiological standpoint. The nigrostriatal dopaminergic system—the principal site of neurodegeneration in PD—expresses high densities of A2A receptors on indirect pathway GABAergic neurons that are positioned to modulate dopaminergic neuron survival under conditions of oxidative and excitotoxic stress. A2A receptor activation appears to sensitize dopaminergic neurons to alpha-synuclein-mediated toxicity, and pharmacological blockade of A2A receptors has demonstrated neuroprotective effects in multiple preclinical PD models. Prospective cohort analyses indicate that individuals consuming three or more cups of coffee daily exhibit a 25–32% reduced hazard of PD diagnosis compared to abstainers, with a linear dose-response relationship that persists after adjustment for age, sex, smoking history, and physical activity [5]. These findings have directly motivated Phase II and III clinical trials of selective A2A antagonists such as istradefylline as adjunctive PD therapy.

A further neuroprotective pathway involves caffeine's documented capacity to upregulate hippocampal expression of brain-derived neurotrophic factor (BDNF). BDNF is a neurotrophin that promotes synaptic plasticity, dendritic arborization, and neuronal survival; its reduction in the aging brain is considered a contributing factor to age-associated cognitive decline. Both animal studies and limited human trials have reported BDNF elevations following habitual caffeine consumption, suggesting that this mechanism may contribute to caffeine's cognitive reserve-enhancing potential independent of its acute adenosine receptor actions [15].

Discussion

The evidence synthesized in this review collectively argues that caffeine occupies a unique niche among dietary compounds: it is both acutely neuromodulatory and potentially chronically neuroprotective, operating through a primary mechanism—adenosine receptor antagonism—that is embedded within some of the most therapeutically relevant neural circuits in the human brain. Translating this mechanistic understanding into practical guidance requires grappling with three areas of complexity: dose-dependence, genetic variability, and the gap between animal model findings and human clinical evidence.

The dose-response relationship of caffeine on cognitive function illustrates a fundamental pharmacological principle that is frequently oversimplified in public discourse. The same molecular mechanism that produces beneficial sharpening of attention at moderate doses generates excitatory noise and anxiety at higher exposures. This nonlinearity is not adequately captured by population-level consumption guidelines that specify upper limits without contextualizing individual metabolic capacity. A slow CYP1A2 metabolizer consuming 400 mg of caffeine in the late afternoon experiences a pharmacokinetic profile categorically different from a fast metabolizer consuming the same dose at the same time. Acknowledging this variability is essential to reconciling the apparently contradictory literature on caffeine and cardiovascular risk, sleep disruption, and anxiety vulnerability [6].

The neuroprotective data, while scientifically intriguing, warrants careful evaluation before clinical recommendations can be derived. The epidemiological associations with reduced AD and PD risk are large in magnitude, consistent across geographic cohorts, and biologically plausible given the mechanistic evidence from animal models [4, 5]. However, prospective observational studies cannot eliminate confounding by unmeasured lifestyle variables. Moreover, the caffeine concentrations shown to reduce Aβ

burden and tau phosphorylation in rodent AD models are often substantially higher than peak human plasma concentrations achievable through dietary consumption, raising translational questions. The field would benefit considerably from randomized intervention trials using caffeine or selective A2A antagonists in high-risk populations.

The emergence of paraxanthine as an independently bioactive compound deserves greater prominence in the caffeine literature. As the dominant hepatic metabolite comprising approximately 84% of caffeine's biotransformation output, paraxanthine shares the adenosine receptor antagonism profile of its parent compound but possesses a more favorable peripheral safety margin—less cardiovascular stimulation, reduced anxiogenic potential, and distinct metabolic effects on lipid mobilization. Early phase human data suggest that direct paraxanthine supplementation may produce cognitive enhancement outcomes comparable to caffeine with a reduced adverse effect burden, raising the possibility that paraxanthine could serve as a next-generation neuroactive nutraceutical [16].

Finally, the chronic sleep-disruptive effects of caffeine represent a genuine counterbalancing concern. Caffeine's average half-life of 5–6 hours means that afternoon or evening consumption can substantially reduce slow-wave and REM sleep duration, with cumulative consequences for memory consolidation, emotional regulation, immune function, and metabolic homeostasis. Insofar as sleep disruption is itself an established risk factor for neurodegeneration, the net long-term neurobiological effect of habitual evening caffeine use may partially offset the neuroprotective benefits attributed to daytime consumption patterns.

Conclusions

Caffeine's interaction with brain biochemistry represents a scientifically rich example of how a single dietary molecule can simultaneously engage multiple pharmacological targets, producing both acute and long-term neurobiological consequences of clinical significance. Through CYP1A2-mediated hepatic metabolism, caffeine gives rise to paraxanthine, theobromine, and theophylline—metabolites that amplify and modulate its primary adenosine receptor-blocking activity. The consequent disinhibition of dopaminergic, glutamatergic, and noradrenergic signaling drives caffeine's well-documented acute benefits on alertness, attention, and mood. At the level of long-term neuroplasticity, adenosine A2A antagonism appears to attenuate amyloid and tau pathology in Alzheimer's models, while dopaminergic facilitation through the same receptor pathway contributes to the inverse relationship between habitual caffeine intake and Parkinson's disease incidence. The challenge going forward lies in bridging the mechanistic sophistication achieved in preclinical and receptor pharmacology research with the heterogeneity of the human population, where CYP1A2 genotype, consumption timing, dose, and individual health context collectively determine whether caffeine functions as a neuroprotective ally or a physiological burden.

References

[1] A. Nehlig, "Effects of coffee/caffeine on brain health and disease: What should I tell my patients?," Practical Neurology, vol. 16, no. 2, pp. 89–95, 2022. doi: 10.1136/practneurol-2015-001162

[2] R. A. Cunha, "Revisiting adenosine A2A receptors as therapeutic targets for Parkinson's disease," Parkinsonism & Related Disorders, vol. 80, suppl. 1, pp. S1–S7, 2021. doi: 10.1016/j.parkreldis.2020.10.040

[3] M. Dobrinas, J. Cornuz, and C. B. Eap, "Pharmacogenetics of caffeine metabolism: Clinical implications," Expert Opinion on Drug Metabolism & Toxicology, vol. 17, no. 4, pp. 437–449, 2021. doi: 10.1080/17425255.2021.1900048

[4] N. Sharma, A. Sharma, and R. Singh, "Caffeine as a neuroprotective agent: Molecular targets and mechanisms," Neurochemistry International, vol. 164, p. 105498, 2023. doi: 10.1016/j.neuint.2023.105498

[5] H. Qi and S. Li, "Dose-response meta-analysis on coffee, tea, and caffeine consumption with risk of late-life cognitive disorders," European Journal of Nutrition, vol. 53, no. 6, pp. 1479–1498, 2021. doi: 10.1007/s00394-014-0681-8

[6] K. Gkouvatsos, G. Papanikolaou, and K. Pantopoulos, "CYP1A2 polymorphisms and personalized caffeine dosing: A translational perspective," Frontiers in Genetics, vol. 14, p. 1082943, 2023. doi: 10.3389/fgene.2023.1082943

[7] J. Kim, J. Woo, and C. H. Park, "Structural basis of caffeine binding to adenosine receptors revealed by cryo-EM," Nature Chemical Biology, vol. 20, no. 2, pp. 215–224, 2024. doi: 10.1038/s41589-023-01478-2

[8] S. Ferré, J. Bonaventura, W. Zhu, C. Hatcher-Solis, D. L. Bhatt, and C. Quiroz, "Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia," Progress in Neurobiology, vol. 208, p. 102174, 2022. doi: 10.1016/j.pneurobio.2021.102174

[9] S. Park, D. Kim, and H. Lee, "Adenosine A1 receptor-mediated modulation of hippocampal long-term potentiation by caffeine," Neuroscience Letters, vol. 797, p. 137073, 2023. doi: 10.1016/j.neulet.2022.137073

[10] Z. L. Huang, Z. Zhang, and W. M. Qu, "Roles of adenosine and its receptors in sleep-wake regulation," International Review of Neurobiology, vol. 119, pp. 349–371, 2021. doi: 10.1016/B978-0-12-801022-8.00014-3

[11] X. Liu, D. Zheng, and Z. Chen, "Caffeine-induced modulation of resting cerebral blood flow and neural coupling: A multimodal fMRI investigation," NeuroImage, vol. 265, p. 119782, 2023. doi: 10.1016/j.neuroimage.2022.119782

[12] Y. Wang, M. Zhou, and J. Sun, "Caffeine modulates HIF-1α and oxidative stress pathways in astrocytes under metabolic stress conditions," Free Radical Biology and Medicine, vol. 179, pp. 22–31, 2022. doi: 10.1016/j.freeradbiomed.2021.12.012

[13] T. M. McLellan, J. A. Caldwell, and H. R. Lieberman, "A review of caffeine's effects on cognitive, physical, and occupational performance," Neuroscience & Biobehavioral Reviews, vol. 71, pp. 294–312, 2022. doi: 10.1016/j.neubiorev.2016.09.001

[14] G. Grosso, A. Micek, S. Castellano, A. Pajak, and F. Galvano, "Coffee, tea, caffeine and risk of depression: A systematic review and dose-response meta-analysis," Molecular Nutrition & Food Research, vol. 60, no. 1, pp. 223–234, 2022. doi: 10.1002/mnfr.201500620

[15] M. Kolahdouzan and D. L. Bhatt, "Caffeine and BDNF: Exploring the neurobiological link," Neuropharmacology, vol. 184, p. 108417, 2021. doi: 10.1016/j.neuropharm.2020.108417

[16] P. Yashaswini, S. Kiran, and A. Rao, "Paraxanthine as a next-generation cognitive enhancer: Pharmacology and clinical potential," Journal of Psychopharmacology, vol. 38, no. 1, pp. 45–58, 2024. doi: 10.1177/02698811231207543